Search
Hydromorphone
go.drugbank.com/drugs/DB00327ApprovedIllicitInvestigationalStructurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. … [A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795]
Insulin glargine
go.drugbank.com/drugs/DB00047ApprovedInvestigationalInsulin glargine is also available as the biosimilar, or "follow-on" product, Basaglar in the US and as Abasaglar in the EU. … Insulin is an important treatment in the management of Type 1 Diabetes (T1D), which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able
Mixtures: Suliqua Pen, Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled penCategories: Drugs Used in DiabetesSynthetic camphor
go.drugbank.com/drugs/DB14156ApprovedMixtures: Sano Ti Amo Relief and Repair Pain Relief, Sano Ti Amo Relief and Repair Pain ReliefProducts: Sanar - Arnica Roll OnMonopotassium phosphate
go.drugbank.com/drugs/DB09413ApprovedInvestigationalVet approvedIt can be used in fertilizer mixtures to reduce escape of ammonia by keeping pH low.
Mixtures: Clinimix 3 % G-E - Infusionsbeutel, Clinimix 5 % G-E - InfusionsbeutelCategories: Compounds used in a research, industrial, or household settingEliglustat
go.drugbank.com/drugs/DB09039ApprovedInvestigational[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … [A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide.
Synonyms: N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamidePhenylpropanolamine
go.drugbank.com/drugs/DB00397ApprovedVet approvedWithdrawnCurrently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.
Mixtures: COUGH - EN, COUGH - EN PLUSSimoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedSimoctocog alfa is a fourth-generation BDD FVIII product made in the human embryonic kidney (HEK) cell line. … It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system.
Idecabtagene vicleucel
go.drugbank.com/drugs/DB16665ApprovedInvestigational[L32858] Idecabtagene vicleucel is indicated as a fifth line treatment of adult patients with relapsed or refractory multiple myeloma. … [L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003]
Velpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Velpatasvir as first line therapy … Both Canadian and American guidelines list Epclusa as a first line recommendation for all genotypes of HCV [L852, A19626].
Curcuma xanthorrhiza oil
go.drugbank.com/drugs/DB11265ApprovedNutraceutical_Curcuma xanthorrhiza_ oil is found as an active ingredient in cosmetic and hygienic products, and marketing of products containing _Curcuma xanthorrhiza_ oil is authorized in some European countries including … _Curcuma xanthorrhiza_ oil is extracted from _Curcuma xanthorrhiza_ Roxb., a member of the ginger family (_Zingiberaceae_) that is widely distributed in the region of Southeastern Asia [A33162].